Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | FGB | P02675 | 1/20 | 0.39 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824582 | 1.00 | KDM4E (0.65) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 | |
| Oxalic Acid SCHEMBL27786843 | 0.84 | KDM4E (0.51) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 | |
| SCHEMBL632748 | 0.83 | KDM4E (0.45) | KDM4ECYP2D6MAPTL3MBTL1ALOX15 | |
| SCHEMBL1396167 | 0.83 | KDM4E (0.45) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 | |
| SCHEMBL1160513 | 0.82 | KDM4E (0.49) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 | |
| SCHEMBL24581974 | 0.81 | KDM4E (0.48) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 | |
| SCHEMBL30824561 | 0.81 | KDM4E (0.48) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 | |
| Oxalic Acid SCHEMBL1077806 | 0.81 | KDM4E (0.48) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 | |
| SCHEMBL3401057 | 0.80 | KDM4E (0.67) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL29054527 | 0.79 | KDM4E (0.65) | KDM4ECYP2D6MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054445-A1 | Amide Substituted Quinolines | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1981882-A1 | AMIDE SUBSTITUTED QUINOLINES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | claimed |
| WO-2007086799-A1 | AMIDE SUBSTITUTED QUINOLINES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | claimed |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | CYTOKINETICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20110021483-A1 | Platinum (IV) Complexes | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2011-01-27 | — | — | US | disclosed |
| CN-101778857-A | Platinum (IV) complex compound | PLATCO TECHNOLOGIES PROPRIETAR | 2010-07-14 | — | — | CN | disclosed |
| EP-2170913-A1 | PLATINUM (IV) COMPLEXES | Platco Technologies (Proprietary) Limited (ZA) | 2010-04-07 | — | — | EP | disclosed |
| US-20090054445-A1 | Amide Substituted Quinolines | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| WO-2008155727-A1 | PLATINUM (IV) COMPLEXES | PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) | 2008-12-24 | — | — | WO | disclosed |
| EP-1981882-A1 | AMIDE SUBSTITUTED QUINOLINES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007086799-A1 | AMIDE SUBSTITUTED QUINOLINES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | NAMPT, NNT, NAPRT | KDM4E 3301/4885CYP2D6 2332/4885MAPT 542/4885 |
| US-20090054445-A1 | Amide Substituted Quinolines | RECQL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0 | KDM4E 1830/4885CYP2D6 37/4885MAPT 2929/4885 |
| US-20110021483-A1 | Platinum (IV) Complexes | OTC, OAT, SLC25A11 | KDM4E 3423/4885CYP2D6 1078/4885MAPT 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.